I-131 MIBG Therapy: Physics and Safety

Q: What is I-131 MIBG therapy used for?

I-131 metaiodobenzylguanidine (MIBG) treats tumors that take up norepinephrine through the norepinephrine transporter, including pheochromocytoma and paraganglioma in adults and adolescents and neuroblastoma in children. The molecule is a norepinephrine analog, so it concentrates in these neuroendocrine tumor cells, where the iodine-131 beta emission delivers a localized radiation dose.

I-131 metaiodobenzylguanidine (MIBG) is a targeted radiopharmaceutical therapy that delivers beta radiation to neuroendocrine tumors — pheochromocytoma, paraganglioma, and neuroblastoma — that take up the norepinephrine analog through the norepinephrine transporter. Its physics, dosimetry, and radiation-safety profile differ meaningfully from more familiar I-131 sodium-iodide thyroid therapy, and getting those differences right is what keeps the treatment both effective and compliant. ¹⁴¹⁰

MIBG therapy sits at the intersection of oncology, nuclear-medicine physics, and radiation safety. The same iodine-131 that ablates thyroid tissue is here attached to a molecule that seeks a completely different target, which is why the thyroid must be actively protected, why bone marrow rather than the thyroid becomes the dose-limiting organ, and why patient release requires more than a glance at a default table. ³⁴¹¹

Introduction

Metaiodobenzylguanidine is a synthetic analog of norepinephrine. Cells that express the norepinephrine transporter (NET) — chromaffin cells of the adrenal medulla, sympathetic paraganglia, and neuroblastoma cells — take it up and store it. When MIBG is labeled with iodine-131, that cellular avidity becomes a delivery vehicle for a therapeutic beta emitter, concentrating dose in the tumor while sparing most normal tissue. ⁴⁵

The approach has two major clinical settings. In children, high-activity I-131 MIBG is an established treatment for relapsed or refractory neuroblastoma, often at weight-based activities that require stem-cell support. ⁶⁷⁸ In adults and adolescents, the high-specific-activity product Azedra (iobenguane I-131) became, in 2018, the first FDA-approved therapy specifically for iobenguane-avid, unresectable or metastatic pheochromocytoma and paraganglioma. ¹²¹⁰

This guide covers the underlying I-131 physics, why thyroid blockade is non-negotiable, how the dose is distributed and why marrow limits it, the MIRD-based dosimetry framework, the difference between a dosimetric and a therapeutic dose, and the NRC patient-release rules that govern when and how these patients go home. DRPS supports these programs through its PET/CT and nuclear medicine physics and radiation safety officer services.

Topic Explanation

What I-131 MIBG is and how it works

I-131 MIBG combines a tumor-seeking molecule with a therapeutic radionuclide. The MIBG portion delivers specificity: it enters NET-expressing cells and is stored in neurosecretory granules. The iodine-131 portion delivers the therapy: its beta particles deposit energy over a short range in tissue, damaging the tumor cells that concentrated the tracer. ⁴⁵

The same molecule labeled with I-123 or a lower activity of I-131 is used diagnostically to confirm that a tumor is "MIBG-avid" before therapy — a true theranostic pairing, in which the diagnostic scan selects patients for whom the therapeutic version will actually reach the target. ⁵ A patient whose tumor does not take up the diagnostic tracer will not benefit from the therapeutic dose, which is why the FDA-approved workflow begins with imaging and a dosimetric dose. ¹¹⁰

The clinical settings

For background on where MIBG fits among other radiopharmaceutical therapies, see our overviews of Lu-177 DOTATATE for neuroendocrine tumors and common PET and radiopharmaceutical-therapy isotopes. MIBG differs from those in a key respect: it is an iodine-based therapy, so it carries the thyroid-protection problem that all radioiodine work shares.

Key Technical Principles

Iodine-131 decay physics

Iodine-131 is a reactor-produced radionuclide with a physical half-life of about 8.02 days. It decays by beta-minus emission to xenon-131, with a principal beta particle of maximum energy about 606 keV (mean energy roughly 190 keV) that delivers the therapeutic dose, and a principal gamma ray at 364 keV emitted in about 81% of decays that enables imaging but also drives the external radiation-safety concern. ⁹ The combination of a therapeutic beta and a penetrating, relatively high-abundance gamma is exactly what makes I-131 both useful and demanding: the beta treats, and the gamma escapes the patient to expose staff, family, and the public. ³⁹

The relatively long 8-day physical half-life means that a treated patient remains a meaningful external source for many days, and that decay-in-storage and patient-release timelines are measured in weeks, not hours — a sharp contrast to the short-lived positron emitters used in PET. This is the physics that underlies every downstream safety decision.

Why thyroid blockade is mandatory

A small fraction of the radioiodine label detaches from the MIBG molecule in vivo as free iodide. The thyroid gland concentrates iodide avidly through the sodium-iodide symporter, so without protection this free I-131 would deliver a high, entirely non-therapeutic dose to the thyroid. Thyroid blockade — saturating the gland with stable iodine, typically as potassium iodide (KI) or a saturated solution of potassium iodide (SSKI) — prevents that uptake. For the FDA-approved product, a thyroid-blocking agent begins at least 24 hours before each dosimetric and therapeutic dose and continues for about 10 days after. ¹⁰ This is the mechanistic mirror image of I-131 sodium-iodide thyroid therapy, where the thyroid is the intended target and no blockade is used. ³

Dosimetry and the dose-limiting organ

Because MIBG distributes to tumor and clears through the blood and kidneys, the bone marrow — via the circulating blood — is usually the dose-limiting organ, and myelosuppression is the principal dose-related toxicity. ¹⁶ At the high weight-based activities used in neuroblastoma, marrow suppression can be severe enough to require autologous stem-cell rescue. ⁶⁷

Absorbed-dose estimates follow the MIRD schema, in which the mean absorbed dose to a target region is the sum over source regions of the time-integrated activity multiplied by a radionuclide- and geometry-specific dose factor:

\overset{ˉ}{D} (r_{T}) = r_{S} \sum \tilde{A} (r_{S}) S (r_{T} \leftarrow r_{S})

Here $\tilde{A} (r_{S})$ is the time-integrated activity (the total number of decays) in source region $r_{S}$ , and $S (r_{T} \leftarrow r_{S})$ is the absorbed dose to target region $r_{T}$ per decay in $r_{S}$ . The time-integrated activity is obtained by integrating the measured time–activity curve, which for a mono-exponential clearance with effective decay constant $λ_{e}$ and initial activity $A_{0}$ is:

\tilde{A} = \int_{0}^{\infty} A_{0} e^{- λ_{e} t} d t = \frac{A _{0}}{λ _{e}} = 1.443 \cdot A_{0} \cdot T_{1/2, e}

The effective half-life $T_{1/2, e}$ combines physical and biological clearance:

\frac{1}{T _{1/2, e}} = \frac{1}{T _{1/2, phys}} + \frac{1}{T _{1/2, biol}}

The EANM has published a standard operational procedure specifically for I-131 MIBG internal dosimetry, defining how whole-body, tumor, and organ absorbed doses should be measured and reported. ³ In the high-specific-activity pheochromocytoma program, the highest mean organ absorbed doses were reported for the thyroid and lower large intestine wall, on the order of 1.2 mGy per MBq administered — a reminder that even a blocked thyroid and the bowel receive meaningful dose. ²

Dosimetric versus therapeutic dosing

The FDA-approved Azedra workflow separates a small dosimetric dose from the subsequent therapeutic doses. The dosimetric dose confirms tumor avidity and supports whole-body dosimetry and safety assessment; the therapeutic doses deliver treatment. The two use different weight thresholds, which is a common source of confusion.

Feature	Dosimetric dose	Therapeutic dose
Purpose	Confirm avidity; support dosimetry and safety review	Deliver treatment
Activity (above weight cutoff)	185–222 MBq (5–6 mCi) if > 50 kg	18,500 MBq (500 mCi) if > 62.5 kg
Activity (at/below cutoff)	3.7 MBq/kg (0.1 mCi/kg) if ≤ 50 kg	296 MBq/kg (8 mCi/kg) if ≤ 62.5 kg
Number of doses	1	2, given at least 90 days apart
Thyroid blockade	Yes: −24 h to +10 days	Yes: −24 h to +10 days

Values reflect the FDA-approved iobenguane I-131 prescribing information; the phase 1 study established a maximum tolerated therapeutic activity of about 296 MBq/kg. ¹²¹⁰ In neuroblastoma, a commonly used therapeutic activity is about 18 mCi/kg with stem-cell support, or roughly 12 mCi/kg when stem-cell backup is not available. ⁶⁷⁸

Comparison with I-131 sodium-iodide therapy

Feature	I-131 MIBG (e.g., Azedra)	I-131 sodium iodide (thyroid)
Molecular target	Norepinephrine transporter (NET)	Sodium-iodide symporter (NIS)
Tumor/tissue	Pheochromocytoma, paraganglioma, neuroblastoma	Hyperthyroid gland; differentiated thyroid cancer
Thyroid blockade	Required (protect the thyroid)	Not used (thyroid is the target)
Dose-limiting organ	Bone marrow / blood	Salivary glands, marrow, lungs (diffuse mets)
Radionuclide physics	I-131: 8.02 d, 364 keV γ, 606 keV β max	Identical

The identical radionuclide physics but opposite thyroid strategy is the single most important teaching point for staff who are already familiar with radioiodine thyroid therapy. ³⁹ For the thyroid-therapy side of that comparison, see our guide to I-131 therapy for thyroid cancer.

Clinical Impact

MIBG therapy changes the radiation-safety footprint of a nuclear-medicine service. A 500 mCi therapeutic administration is more than an order of magnitude above the activity at which an I-131 patient can be released under default assumptions, so these patients typically require a shielded inpatient room, contamination controls, and a planned release calculation rather than a same-day discharge. ¹¹¹³

For neuroblastoma, the pediatric setting adds complexity: small patients, parental presence, and the practical reality that a frightened child cannot be left unattended. Radiation-safety planning must balance the child's needs against dose to caregivers, and it depends on careful shielding, time-and-distance discipline, and clear instructions. ⁶⁸

The circulating-blood, marrow-limited dosimetry also shapes the treatment course: because toxicity is hematologic rather than local, blood counts, cumulative activity, and — in the approved workflow — a dosimetric assessment guide whether and how the therapeutic doses proceed. ¹²

Practical Optimization Tips

A defensible I-131 MIBG program combines pharmacy, physics, and radiation-safety planning before the first dose is drawn.

1. Confirm avidity before committing to therapy

Use the diagnostic MIBG scan to confirm the tumor concentrates the tracer. A non-avid tumor will not respond, and the dosimetric dose in the approved workflow exists precisely to verify uptake and support dosimetry before the large therapeutic activity. ¹⁵

2. Start and document thyroid blockade correctly

Begin the thyroid-blocking agent on schedule (at least 24 hours before the dose for the approved product) and continue it for the full post-therapy period. Document the regimen — free radioiodide is unavoidable, so blockade is the only defense for the thyroid. ¹⁰

3. Plan the room, shielding, and contamination controls

Treat the patient room as a temporary radioactive-materials area: removable-surface protection, dedicated waste handling, survey instruments, and staff dose monitoring. I-131's 364 keV gamma is penetrating, so structural and mobile shielding, distance, and time all matter. See our guidance on choosing the right radiation survey meter and nuclear medicine decontamination best practices.

4. Do the release calculation with real data

For high therapeutic activities, the default release table will not apply. Use measured dose rates at 1 meter and the patient's effective half-life (physical plus biological clearance), and document the assumptions. Because dose to others will usually exceed 1 mSv, written instructions are mandatory. ¹¹¹³

5. Instruct the patient and family clearly

Give practical, written radiation-safety instructions covering distance, sleeping arrangements, bathroom hygiene, laundry, and contact with children and pregnant persons, scaled to the patient's measured dose rate and expected decay. ¹¹¹³

Common pitfalls to avoid

Confusing the two weight cutoffs. The dosimetric-dose threshold (50 kg) and the therapeutic-dose threshold (62.5 kg) are different. ¹⁰
Under-scheduling thyroid blockade. Starting KI late or stopping it early leaves the thyroid exposed to free radioiodide. ¹⁰
Assuming same-day release. Therapeutic MIBG activities usually require a patient-specific release calculation and often inpatient decay. ¹¹
Treating marrow dose as an afterthought. Marrow is the dose-limiting organ; hematologic toxicity, not thyroid dose, drives the safety margin. ¹⁶
Skipping dosimetry. The approved workflow builds in a dosimetric dose for a reason; whole-body and organ dosimetry inform both efficacy and safety. ²³

Regulatory Considerations

I-131 MIBG is byproduct material regulated under NRC or Agreement State medical-use rules, and patient release is governed by a specific federal framework. The therapy requires an authorized user, a written directive, and adherence to the medical-use requirements of 10 CFR Part 35. ¹²

The core patient-release rules are:

10 CFR 35.75(a) — a licensee may release a patient administered radioactive material if the total effective dose equivalent to any other individual from the released patient is not likely to exceed 5 mSv (0.5 rem). ¹¹
10 CFR 35.75(b) — the licensee must provide the released patient (or the patient's guardian) with written radiation-safety instructions whenever the dose to any other individual is likely to exceed 1 mSv (0.1 rem), including instructions on interrupting breastfeeding where applicable. ¹¹
NRC Regulatory Guide 8.39, Revision 1 — provides the methodology and the default activity/dose-rate tables used to demonstrate compliance. For I-131, the default table entry corresponds to a releasable activity of about 1.2 GBq (33 mCi) at a dose rate near 0.07 mSv/h (7 mrem/h) at 1 meter. Above that activity, release must rest on a patient-specific calculation. ¹³
10 CFR 35.2075 — requires the licensee to retain records of the basis for release when release is based on retained activity, an occupancy factor less than 0.25 at 1 meter, or measured effective half-life; these records are kept for 3 years. ¹²

Because a 500 mCi therapeutic dose is roughly fifteen times the default I-131 release activity, MIBG patients typically cannot be released under the table alone. Release requires measured dose rates, an effective-half-life calculation, usually a period of inpatient decay, mandatory written instructions, and retained records. ¹¹¹³ For the broader patient-release picture, see patient release after radiopharmaceutical therapy.

Jurisdiction depends on location. Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, New York, Pennsylvania, and New Jersey are NRC Agreement States that administer equivalent medical-use programs, while Washington, DC and Delaware are regulated directly by the NRC. Confirm the authority having jurisdiction and its specific requirements before administering therapy. ¹²

Frequently Asked Questions (FAQs)

What is I-131 MIBG therapy used for?

I-131 metaiodobenzylguanidine treats tumors that take up norepinephrine through the norepinephrine transporter, including pheochromocytoma and paraganglioma in adults and adolescents and neuroblastoma in children. The molecule is a norepinephrine analog, so it concentrates in these neuroendocrine tumor cells, where the iodine-131 beta emission delivers a localized radiation dose. ¹⁴⁶

Why is thyroid blockade required before MIBG therapy?

A small fraction of the I-131 detaches from the MIBG molecule as free radioiodide, which the thyroid gland avidly takes up and where it can deliver a high thyroid dose. A thyroid-blocking agent such as potassium iodide saturates the gland so it does not concentrate free radioiodide. For the FDA-approved product, blockade begins at least 24 hours before each dose and continues for about 10 days after. ¹⁰

What is the dose-limiting organ in MIBG therapy?

Bone marrow, through the circulating blood, is usually the dose-limiting organ in I-131 MIBG therapy, and myelosuppression is the principal toxicity. High therapeutic activities, especially in neuroblastoma, may require autologous stem-cell support. Dosimetry therefore focuses heavily on whole-body and blood or marrow absorbed dose. ¹⁶⁷

Can a patient be released after I-131 MIBG therapy?

Release depends on the administered activity and the projected dose to others. Under NRC rules, a patient may be released when the total effective dose equivalent to any other individual is not likely to exceed 5 mSv. High therapeutic MIBG activities usually exceed the default release table, so release requires a patient-specific calculation using measured dose rates and effective half-life, often after a period of inpatient decay, plus written radiation-safety instructions. ¹¹¹³

How is I-131 MIBG different from I-131 sodium iodide thyroid therapy?

Both use the same radionuclide, iodine-131, but they target different tissues. Sodium iodide is taken up by the thyroid through the sodium-iodide symporter to treat hyperthyroidism or thyroid cancer. MIBG is taken up by neuroendocrine tumor cells through the norepinephrine transporter, and it requires thyroid blockade precisely to keep iodine out of the thyroid. The radionuclide physics are identical; the biological target and dose-limiting organ differ. ³⁹

What is Azedra?

Azedra (iobenguane I-131) is a high-specific-activity I-131 MIBG product approved by the FDA in 2018 for iobenguane-scan-positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma in patients 12 years and older who require systemic anticancer therapy. It is dosed as an initial dosimetric dose followed by two therapeutic doses given at least 90 days apart. ¹¹⁰

Key Takeaways

MIBG is a norepinephrine analog. It targets NET-expressing tumors — pheochromocytoma, paraganglioma, and neuroblastoma — making I-123/I-131 MIBG a genuine theranostic pairing. ⁴⁵
I-131 physics drive the safety plan. An 8.02-day half-life, a 606 keV therapeutic beta, and a penetrating 364 keV gamma in ~81% of decays mean days-long external exposure and careful release planning. ⁹
Thyroid blockade is mandatory. Free radioiodide would otherwise irradiate the thyroid; KI/SSKI from −24 hours to +10 days protects it. ¹⁰
Marrow is the dose-limiting organ. Myelosuppression, not thyroid dose, sets the safety margin; high pediatric activities may need stem-cell support. ¹⁶⁷
Dosimetric and therapeutic doses differ. They use different weight cutoffs, and dosimetry follows the MIRD schema and the EANM SOP. ²³¹⁰
Release is calculation-based. Therapeutic activities exceed the default I-131 release table, so 10 CFR 35.75 compliance rests on measured dose rates, effective half-life, written instructions, and retained records. ¹¹¹²¹³

Conclusion

I-131 MIBG therapy is a powerful, target-specific treatment for neuroendocrine tumors, but it borrows a radionuclide famous for a completely different job. The physics that make iodine-131 useful for thyroid ablation — a therapeutic beta and a penetrating gamma over an 8-day half-life — are exactly what make MIBG demanding: the thyroid must be actively protected, the marrow becomes the limiting organ, and patient release is a documented calculation rather than a default. A program that treats MIBG as its own discipline, with dosimetry, thyroid blockade, shielding, and a defensible release plan built in from the start, is one that protects patients, staff, families, and the public alike. ¹³¹¹

How DRPS Can Help

Diagnostic Radiation Physics Services (DRPS) supports nuclear-medicine and radiopharmaceutical-therapy programs with authorized-user and RSO consulting, written-directive and procedure development, dosimetry support, patient-release calculations, room shielding and contamination-control planning, and staff training aligned with 10 CFR Part 35 and NRC or Agreement State requirements.

DRPS provides PET/CT and nuclear medicine physics, radiation safety officer, and radioactive material license support across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware.

A strong therapy program makes the safe workflow the routine workflow — before the first dose is drawn.

Related Resources

References

Pryma DA, Chin BB, Noto RB, Dillon JS, Perkins S, Solnes L, et al. Efficacy and safety of high-specific-activity I-131 MIBG therapy in patients with advanced pheochromocytoma or paraganglioma. Journal of Nuclear Medicine. 2019;60(5):623-630. doi:10.2967/jnumed.118.217463. doi.org
Noto RB, Pryma DA, Jensen J, Lin T, Stambler N, Strack T, et al. Phase 1 study of high-specific-activity I-131 MIBG for metastatic and/or recurrent pheochromocytoma or paraganglioma. Journal of Clinical Endocrinology & Metabolism. 2018;103(1):213-220. doi:10.1210/jc.2017-02030. doi.org
Gear J, Chiesa C, Lassmann M, Gabiña PM, Tran-Gia J, Stokke C, Flux G. EANM Dosimetry Committee series on standard operational procedures for internal dosimetry for I-131 mIBG treatment of neuroendocrine tumours. EJNMMI Physics. 2020;7(1):15. doi:10.1186/s40658-020-0282-7. doi.org
Giammarile F, Chiti A, Lassmann M, Brans B, Flux G. EANM procedure guidelines for I-131-meta-iodobenzylguanidine (I-131-mIBG) therapy. European Journal of Nuclear Medicine and Molecular Imaging. 2008;35(5):1039-1047. doi:10.1007/s00259-008-0715-3. doi.org
Bombardieri E, Giammarile F, Aktolun C, Baum RP, Bischof Delaloye A, Maffioli L, et al. I-131/I-123-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging. European Journal of Nuclear Medicine and Molecular Imaging. 2010;37(12):2436-2446. doi:10.1007/s00259-010-1545-7. doi.org
Matthay KK, Yanik G, Messina J, Quach A, Huberty J, Cheng SC, et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. Journal of Clinical Oncology. 2007;25(9):1054-1060. doi:10.1200/JCO.2006.09.3484. doi.org
Matthay KK, Tan JC, Villablanca JG, Yanik GA, Veatch J, Franc B, et al. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma. Journal of Clinical Oncology. 2006;24(3):500-506. doi:10.1200/JCO.2005.03.6400. doi.org
DuBois SG, Chesler L, Groshen S, Hawkins R, Goodarzian F, Shimada H, et al. Phase I study of vincristine, irinotecan, and I-131-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma. Clinical Cancer Research. 2012;18(9):2679-2686. doi:10.1158/1078-0432.CCR-11-3201. doi.org
International Commission on Radiological Protection. ICRP Publication 107: Nuclear Decay Data for Dosimetric Calculations. Annals of the ICRP. 2008;38(3). icrp.org
U.S. Food and Drug Administration. Azedra (iobenguane I 131) injection prescribing information. NDA 209607; 2023 revision. accessdata.fda.gov
U.S. Nuclear Regulatory Commission. 10 CFR 35.75: Release of individuals containing unsealed byproduct material or implants containing byproduct material. ecfr.gov
U.S. Nuclear Regulatory Commission. 10 CFR 35.2075: Records of the release of individuals. ecfr.gov
U.S. Nuclear Regulatory Commission. Regulatory Guide 8.39, Revision 1: Release of Patients Administered Radioactive Material. 2020. nrc.gov